STOCKHOLM, November 3, 2015 – In accordance with the resolution passed by Elekta’s (EKTA-B.ST) Annual General Meeting on September 1, 2015, the Chairman of the Board has contacted the company’s four largest shareholders in terms of votes, in addition to the shareholder or shareholders represented by the Chairman himself, each of whom expressed an interest in participating in the Nomination Committee, and appointed one member (see below) to form Elekta’s Nomination Committee together with the Chairman of the Board. The procedure is described in detail in the notice of the 2015 Annual General Meeting. Nomination Committee members: · Laurent Leksell, in his capacity as Chairman of the Board of Elekta and representing his own and related parties’ holdings · Åsa Nisell, appointed by Swedbank Robur funds · Per Colleen, appointed by the Fourth Swedish National Pension Fund · John Hernander, appointed by Nordea Investment funds · Mikael Wiberg, appointed by Alecta The Nomination Committee will appoint one of its members as Chairman. The Nomination Committee is to present proposals for resolutions by the 2016 Annual General Meeting of Shareholders in relation to the following: Chairman of the Annual General Meeting of Shareholders, Chairman of the Board of Directors and other members of the Board of Directors, Fees to the Board of Directors broken down into amounts for the Chairman of the Board of Directors, other members of the Board of Directors and members of the Board of Directors’ committees, External auditor and fees to the auditor, and where deemed necessary, proposal to amend the procedure for the Nomination Committee. Shareholders wishing to submit proposals to Elekta’s Nomination Committee can do so by e-mail at valberedningen@elekta.com or by letter to: Elekta AB, Nomination Committee Box 7593 SE-103 93 Stockholm Sweden # # # For further information, please contact: Johan Andersson, Director, Investor Relations, Elekta AB Tel: +46 702 100 451, e-mail: johan.andersson@elekta.com Time zone: CET: Central European Time Gert van Santen, Group Vice President Corporate Communications, Elekta AB Tel: +31 653 561 242, e-mail: gert.vansanten@elekta.com Time zone: CET: Central European Time The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 07:30 CET on November 3, 2015. About Elekta Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both health care providers and patients, Elekta aims to improve, prolong and even save patient lives. Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,800 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on NASDAQ Stockholm. Website: www.elekta.com.
Elekta’s Nomination Committee for the 2016 Annual General
Top 10 Most Recent News Articles
AppLovin Legal Woes: A Deep Dive into Investor Claims
AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...
Continue Reading
Webull Faces Class Action: Key Details for Investors
What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...
Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries
JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...
Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut
Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...
Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing
Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...
Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched
Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...
Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results
Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...
Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss
Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...
Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine
Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...
Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG
New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...
Continue ReadingTop 5 Most Recently Viewed Articles
C3is Inc (CISS) Hits 52-Week Low; Analyzing Market Challenges
C3is Inc (CISS) hit a new low recently, dropping to $1.09 a share. This marks a staggering 97.53% decline over the past year, leaving investors scratching their heads about where this company is headed next. C3is Inc: A Company in Crisis As the stock tumbles to its 52-week low, the implications for C3is's market position are glaring. With a market cap of just $6.75...
Continue Reading
Securitas AB Set to Release Q3 2025 Financial Results Soon
Securitas AB Announces Release of Q3 2025 Results STOCKHOLM, Oct. 29, 2025 - Securitas AB is gearing up to publish its Interim Report for the period of January to September 2025 on Thursday, November 6, 2025, at 8:00 a.m. CET. This important financial document will provide insights into the company's performance and outlook for the future. Details of the Report Release...
Continue Reading
XRP Whales Drive Demand for ExoraPad's $EXP as Presale Surges
XRP Whales Drive Demand for ExoraPad's $EXP as Presale Surges In a remarkable show of confidence, XRP whales are actively positioning themselves to acquire ExoraPad's $EXP tokens, resulting in a presale that has quickly exceeded expectations. This impressive feat has occurred just hours after the presale launch, where over 30% of the softcap has already been raised,...
Continue Reading
Innovative Partnership for Elderly Services and Board Changes
Strengthening Services for the Elderly CLIK is thrilled to announce its exciting new partnership with Flash Mutual, a cutting-edge technology firm operating under Tencent's Sustainable Social Value initiatives. This collaboration is designed to deliver round-the-clock instant device services specifically aimed at enhancing the lives of senior citizens. A Focus on...
Continue Reading
Microsoft's Fourth-Quarter Forecast: Anticipating Growth and Innovation
Overview of Microsoft's Upcoming Fourth Quarter Earnings Microsoft Corporation (NASDAQ: MSFT) is positioning itself for a robust financial report as it gears up to share its fourth-quarter results. Analysts are excited about the anticipated growth driven by advancements in AI and cloud services, highlighting the company's impressive trajectory in the tech sphere. Earnings...
Continue Reading